ArticleMolecular imaging and radionuclide therapy2020
The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer
Article in Molecular imaging and radionuclide therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- The Relationship between D'Amico and ISUP Risk Classifications andCurrent oncology (Toronto, Ont.) · 2024Article
- A Comprehensive Analysis of VolumetricMolecular imaging and radionuclide therapy · 2024Article
- What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?World journal of urology · 2023Review
- Characteristics of Radiopharmaceutical Uptake in Primary Tumor and Metastatic Lesions of Prostate Carcinoma: Comparison of Oligometastatic with Multimetastatic Disease.Molecular imaging and radionuclide therapy · 2023Article
- Survival Outcomes After Radiotherapy for the Treatment of Synchronous Oligometastatic Prostate Cancer.JAMA network open · 2022Article
- TheFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: In this study, we aimed to investigate whether Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) scanning is adequate to predict intermediate risk, high risk, or oligometastatic prostate cancer (PCa) as an initial staging modality. Methods: The Ga-68 PSMA PET/CT scan images of 50 PCa patients pathologically proven by transrectal ultrasound guided biopsy were evaluated retrospectively. The association of standard uptake value maximum (SUV Results: The SUV Conclusion: In this paper, we demonstrated the association between SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.